Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

3
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
3
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

4.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning to predict venous thrombosis in acutely ill medical patients.

Research and practice in thrombosis and haemostasis·2020
Same author

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.

JAMA cardiology·2020
Same author

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation.

Journal of thrombosis and thrombolysis·2020
Same author

Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.

Journal of the American College of Cardiology·2020
Same author

The AngelMed Guardian<sup>®</sup> System in the Detection of Coronary Artery Occlusion: Current Perspectives.

Medical devices (Auckland, N.Z.)·2020
Same author

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Nature reviews. Cardiology·2020

Related Experiment Video

Updated: Jun 6, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

198

International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention:

Dominick J Angiolillo1, Mattia Galli2, Dimitrios Alexopoulos3

  • 1Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.

JACC. Cardiovascular Interventions
|November 27, 2024
PubMed
Summary

Personalizing antiplatelet therapy after coronary interventions is crucial. Platelet function and genetic testing can guide the selection of P2Y12 inhibitors to balance bleeding and clotting risks.

Keywords:
P2Y(12) inhibitorgenetic testingguided antiplatelet therapypercutaneous coronary interventionplatelet function testingprecision medicine

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

790

Related Experiment Videos

Last Updated: Jun 6, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

198
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

790

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Practice

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard after percutaneous coronary interventions.
  • DAPT increases bleeding risk, necessitating individualized treatment strategies.
  • Balancing bleeding and ischemic risks in patients is challenging.

Purpose of the Study:

  • To provide expert recommendations on using platelet function and genetic testing to personalize P2Y12 inhibitor selection.
  • To address the gap in current guidelines regarding the clinical implementation of these tests.

Main Methods:

  • Review of current evidence on pharmacodynamic profiles of oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor).
  • Analysis of data on high residual platelet reactivity and low platelet reactivity.
  • Consensus development by a panel of international experts.

Main Results:

  • Up to one-third of clopidogrel users show high residual platelet reactivity, increasing thrombotic risk.
  • Prasugrel and ticagrelor are associated with low platelet reactivity and increased bleeding risk in some patients.
  • Platelet function and genetic testing can guide P2Y12 inhibitor selection, but trial results are nonuniform.

Conclusions:

  • Expert consensus provides guidance on tailoring antiplatelet therapy based on individual patient risk.
  • Platelet testing may optimize P2Y12 inhibitor choice to improve outcomes after percutaneous coronary intervention.
  • Further research and guideline updates are needed for widespread implementation.